AI boom, small-cap rally, and record leverage — pick your poison.

Buy Nvidia — Two sources confirm AI supply chain tightness and a fund manager's explicit buy — NVDA is the purest play; forward P/E 15.3 is not extreme given the growth.

Buy TSMC — TSMC's capacity constraints are flagged by Nikkei Asia as a bottleneck; 9% below its 52-week high leaves room for AI-driven re-rating.

Buy SK Hynix — Memory leader and explicit fund manager pick from MarketWatch — the $600bn Korea chip plan is a multi-year tailwind.

Buy Samsung — Samsung is building new plants as part of Korea's chip mega-expansion, positioning it for AI memory and foundry demand.

Buy Apple — Apple plans five new iPhones to grab market share during the memory crunch — a bold offensive that supports the hardware bull case.

Hold Tech sector — The fund manager rotated out of software — XLK contains both hardware and software, so the net signal is mixed.

Sell Apollo Global — Two FT sources confirm exit difficulties linked to immigration raids — a fresh policy risk that isn't priced into consensus estimates.

Hold Novo Nordisk — WSJ's Medicare math is sobering — limited upside means the stock's discount may be justified; hold until visibility improves.

Hold Eli Lilly — Lilly at 2% below 52-week high and 27x forward P/E — the Medicare disappointment could knock it off the top.

Buy Euro — Multibank caution on the dollar — no explicit quote, but the clustering of contrarian views is the signal.

Buy Bitcoin — Bitwise's cycle-bottom call, though single-source, aligns with institutional flow expectations.

Hold Strategy — The STRC selloff is tied to MSTR's leverage — if institutions replace it, MSTR's edge fades; watch, don't chase.

Buy BYD — Overseas sales surging 70% per Nikkei — the European market share win is a credible long-term growth driver.

Sell Nissan — Nikkei notes Nissan pivoting away from Europe as Chinese brands eat share — negative momentum.

Sell Toyota — Japan's largest automaker is likely losing European volume to Chinese EV imports, albeit slowly.

Hold China internet — Consumer weakness may hit e-commerce, but AI-driven '618' sales provide a cushion — wait for clearer data.

Sell China large caps — Nikkei's June sales collapse is a clear cyclical headwind — FXI at 2% above 52-week low suggests the market hasn't fully discounted the weakness.

Sell BYD — BYD's domestic sales already fell 16% in H1; subsidy withdrawal compounds the pain, even as Europe booms — conflicting signals.

Buy Aerospace & defense — Two sources on a massive defense startup funding round confirm the sector's attractiveness; ITA near highs but momentum solid.

Buy Russell 2000 — Goldman's explicit triple-catalyst call supports small-cap outperformance; IWM at 52-week highs suggests momentum can continue.

Buy Biotech — Biotech is a named catalyst and XBI is at peak levels — the rally has legs if the innovation cycle continues.

Buy Natural gas — Qatar LNG supply disruption per Bloomberg — UNG's deep discount to highs offers a potential squeeze play.

Hold Oil — Oil flows are normalizing through Hormuz, so the LNG story is separate; USO is up 50% YTD — wait for Saudi export impact.

Buy Saudi equities — Higher oil export volumes directly boost Saudi economic activity and corporate earnings — KSA is a clean play.

Sell Oil — Bloomberg reports record Saudi crude flows post-truce — a clear supply headwind for oil, especially after a 50% YTD rally.

Buy Volatility — Record leverage makes a volatility spike likely — VIXY is 56% below its 52-week high and priced for calm.

Sell S&P 500 — Systemic leverage could trigger forced selling; SPY near all-time highs leaves little room for error.

Buy Dentsu — Privatization of a subsidiary could unlock value and signal restructuring progress — a catalyst for the beaten-down ad giant.

Hold Fujitsu — Fujitsu's investment is a non-core strategic move, unlikely to move the needle for its own stock.